Open-label, Phase 1, four way crossover study to compare the PK of the new ferric maltol suspension, in healthy volunteers, with the existing ferric maltol capsules under fed and fasted conditions.~32 subjects will be randomised to 1:1:1:1 ratio to receive one of the treatment sequences.~Based on the randomised sequence, subjects will receive a single dose of 30mg ferric maltol capsule in a fed/ fasted condition and 30 mg (5ml) ferric maltol suspension in a fed/ fasted condition.~Subject participation in the study will consist of 3 periods:~Screening: up to 14 days~Randomised treatment: 8 days~Post-treatment follow up: 3-7 days following drug discontinuation
The purpose of the study is to compare the Pharmacokinetics (PK) of the new ferric maltol suspension, in adults, with the existing ferric maltol capsule.